2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2376

Something for Us: Client Perspectives on Lupus Self-Management Programming Using the 5-a Behavior Change Model

Patient Outcomes, Preferences, and Attitudes Poster II – ARHP

9:00AM-11:00AM: Abstract Number: 2187

Specialist Link Telephone Advice Cost Effectively Enhances Rheumatology Patient Care in Alberta, Canada

Health Services Research Poster III – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 2045

Specific Anti-Citrullinated Protein Antibodies Profiles Are Associated with Rheumatoid Arthritis Related Interstitial Lung Disease

Rheumatoid Arthritis – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2312

Spontaneous Vertebral Fractures after Denosumab Discontinuation

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1959

Stability of DNA Methylation Signature in Primary RA Synovial Fibroblasts Compared with Cultured Fibroblast-like Synoviocytes

Genetics, Genomics and Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2453

Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2126

STAT4 Activation By Type I Interferons Regulates Pathogenic IL-21 and IFN-γ in Lupus

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2197

Steroid Bolus Leads to a Negative 18f-FDG PET/CT Scan in Large Vessel Vasculitis. Data from a Multicenter Giant Cell Arteritis Cohort Database

Imaging of Rheumatic Diseases Poster III: Other Modalities

9:00AM-11:00AM: Abstract Number: 2460

Study of Sixteen Cases of Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders Developed in Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: L02

Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis

Late-Breaking Abstract Poster Session

9:00AM-11:00AM: Abstract Number: 2378

Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category

Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

9:00AM-11:00AM: Abstract Number: 2293

Subcutaneous Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Analysis of a Monocentric Cohort

Muscle Biology, Myositis and Myopathies Poster III: Treatment and Classification Criteria

9:00AM-11:00AM: Abstract Number: 2299

Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2038

Subgroups By the Peripheral Immunophenotyping and Different Responses to Biological Dmards in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2609

Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].